clinical trial · NCT05894343
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
MeiraGTx, LLC·phase2·active not recruiting·n = 13
Parkinson's DiseaseAAV-GAD
brief summary
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
started
May 19, 2023
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Aug 17, 2025
detailed description
The duration of individual participation in this study will be approximately 54 months for participants who received AAV-GAD in Study MGT-GAD-025 and approximately 60 months for participants who received sham surgery in Study MGT-GAD-025.
official title
Long-term Follow-up of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol